Robotic surgery is growing, procedures are climbing, and da Vinci 5 is rolling out. Is Intuitive Surgical's premium valuation worth paying?
Robotic surgery is growing, procedures are climbing, and da Vinci 5 is rolling out.
Is Intuitive Surgical's premium valuation worth paying?
Intuitive Surgical (ISRG +0.50%) has built a leading position in robot-assisted surgery, and three Wall Street analysts see its shares reaching $500. Oppenheimer upgraded the stock to Outperform in August with a $500 price target. Meanwhile, Citigroup and Baird lowered their targets to $500 in July but kept their Buy and Outperform ratings.
As more hospitals adopt its technology, the company is finding new ways to accelerate growth. Here's why the bull case may have more room to run.
Robotic surgery gives Intuitive Surgical a powerful growth engine
Intuitive Surgical's bull case is straightforward: it isn't just selling surgical robots; it's building a whole ecosystem that hospitals and surgeons can rely on for years. Its flagship da Vinci surgical system allows surgeons to perform minimally invasive procedures using robotic tools through a console.
But the bigger revenue driver is what happens after a hospital purchases a robot.
Intuitive can generate recurring revenue from instruments, accessories, and servicing as hospitals continue to use its systems. That creates a business model with both a sales component for equipment and an ongoing revenue stream from surgical procedures.
The company's next major opportunity comes from Intuitive's latest platform, da Vinci 5. The system builds on established technology with features such as improved imaging, enhanced computing capabilities, and tools to support surgical workflows. If it succeeds, da Vinci 5 could encourage new purchases, upgrades, and broader adoption across hospitals.
The new rollout is already underway. In the second quarter of 2026, Intuitive placed 246 da Vinci 5 systems, up from 180 in the previous year. That suggests that the new platform is already contributing to more overall sales.
Averytin News Financial update.